Concr
concr.co
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Overview
Concr is a London biotechnology company founded in 2020 that models tumour biology to predict how patients will respond to cancer drugs. Its FarrSight platform simulates treatment on virtual patients so that trial designs and prescribing decisions can be tested computationally. The company works with pharmaceutical developers and clinical research groups.
News
Regulating complexity in AI-enabled omics and multi-omics technologies for precision medicine
The convergence of (multi-)omics and artificial intelligence is transforming precision medicine by enabling data-driven diagnostics, treatment prediction, and patient stratification. Yet, regulatory frameworks lag behind this innovation. This commentary d
Read more
Report
CariGenetics Partners With Concr Tech Firm
Concr - which was described as a "deeptech company dedicated to enabling precision medicine and improving drug development using predictive analytics and artificial intelligence AI" - announced its partnership with CariGenetics. A spokesperson said,
Read more
Report
Bayesian Digital Twins Show Potential For Predicting Prognosis And Treatment Response
Learn how Bayesian digital twins are trained, validated, and trusted in clinical settings and explore the potential for integrating these models into interventional trials.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
London
United Kingdom
HQ
Investors
Regent House, 316a Beulah Hill, London, SE19 3HF